Michael J. Morin

Michael J. Morin, Ph.D. has been the Chief Scientist since August 2021. Prior to that, Dr. Morin served as the Chief Scientific Officer since May 2019 and served as the Chief Executive Officer from March 2017 to May 2019. Dr. Morin previously served on the Board from March 2017 to August 2020. Prior to originally joining us as Chief Scientific Officer in January 2017, Dr. Morin served as an independent consultant to the biotechnology industry, including us, from September 2015 to March 2017, and he served as the Chief Scientific Officer of Onkaido Therapeutics LLC from June 2014 to September 2015. He has also served as the Chief Executive Officer of Supportive Therapeutics, LLC, and held various roles, including Vice President in Global Research and Development at Pfizer, Inc., where he led Antibacterials, Immunology, and Cancer Drug Discovery. Dr. Morin received his B.Sci. in Biological Sciences from the University of Lowell (now the University of Massachusetts Lowell) and his Ph.D. in Cancer Pharmacology from the State University of New York at Buffalo (Roswell Park Graduate Division). Dr. Morin completed his postdoctoral work as an NIH postdoctoral fellow at the Yale Comprehensive Cancer Center.